中国实用医药
中國實用醫藥
중국실용의약
CHINA PRACTICAL MEDICAL
2009年
17期
52-54
,共3页
局部晚期鼻咽癌%放化疗%不良反应
跼部晚期鼻嚥癌%放化療%不良反應
국부만기비인암%방화료%불량반응
Locally advanced nasopharyngeal carcinoma%Radiotherapy and chemotherapy%Toxicity
目的 观察放化疗对局部晚期鼻咽癌的临床疗效和安全性.方法 将70例局部晚期鼻咽癌患者随机分为放化疗组和单放疗组,各35例.比较两组疗效和不良反应.结果 两组肿瘤消退率(CR+PR)分别为91.4%和65.7%,差异有统计学意义(P<0.05).两组病例均有不同程度的口腔黏膜、消化道反应和外周血白细胞(WBC)下降,差异无统计学意义(P>0.05).结论 同期放化疗治疗能提高局部晚期鼻咽癌的生存率和局部控制率,减少远处转移;放化联合治疗不良反应可耐受.
目的 觀察放化療對跼部晚期鼻嚥癌的臨床療效和安全性.方法 將70例跼部晚期鼻嚥癌患者隨機分為放化療組和單放療組,各35例.比較兩組療效和不良反應.結果 兩組腫瘤消退率(CR+PR)分彆為91.4%和65.7%,差異有統計學意義(P<0.05).兩組病例均有不同程度的口腔黏膜、消化道反應和外週血白細胞(WBC)下降,差異無統計學意義(P>0.05).結論 同期放化療治療能提高跼部晚期鼻嚥癌的生存率和跼部控製率,減少遠處轉移;放化聯閤治療不良反應可耐受.
목적 관찰방화료대국부만기비인암적림상료효화안전성.방법 장70례국부만기비인암환자수궤분위방화료조화단방료조,각35례.비교량조료효화불량반응.결과 량조종류소퇴솔(CR+PR)분별위91.4%화65.7%,차이유통계학의의(P<0.05).량조병례균유불동정도적구강점막、소화도반응화외주혈백세포(WBC)하강,차이무통계학의의(P>0.05).결론 동기방화료치료능제고국부만기비인암적생존솔화국부공제솔,감소원처전이;방화연합치료불량반응가내수.
Objective To observe the clinical efficacy and safety of radiotherapy and chemotherapy for locally advanced nasopharyngeal cancer.Methods 70 cases of locally advanced nasopharyngeal cancer wererandomly divided into the radiotherapy and chemotherapy group and the single-radiotherapy group,35 cases in each group.Compared efficacy and toxicity of two groups.Results Tumor regression rate of two groups(CR+PR)were separately 91.4% and 65.7% ,the difference had statistical significance(P<0.05).Two groups of patients had varying degrees of oral mucosa,gastrointestinal reactions and decreased peripheral blood WBC,there was no significant difference(P>0.05).Conclusion This prospective study has demonstrated that concomitant radiochemotherapy can improve the survival and local disease control,and delay the distant metastasis and be well tolerated in the patients with advanced nasopharyngea1 carcinoma.
